Core Viewpoint - Hainan Haiyao announced that its stock experienced an abnormal trading fluctuation, with a cumulative price increase of over 20% on November 14 and November 17, 2025, and confirmed that there are no undisclosed significant information affecting the stock price [1] Summary by Relevant Sections - **Stock Performance** - The stock price of Hainan Haiyao showed a cumulative increase of over 20% across two consecutive trading days [1] - **Company Disclosure** - The company stated that there are no corrections or supplements needed for previously disclosed information [1] - No recent media reports have been identified that could significantly impact the company's stock trading price [1]

海南海药公告称，公司股票于2025年11月14日、11月17日连续2个交易日收盘价格涨幅偏离值累计达 20%以上，属于异常波动。经核查，公司前期披露信息无需更正补充，近期经营正常，内外部环境无重 大变化，公司、控股股东和实控人无应披露未披露重大事项，异常波动期间未买卖公司股票。公司提醒 投资者以指定媒体公告信息为准。 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-070 海南海药股份有限公司 关于股票交易异常波动公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 海南海药股份有限公司（以下简称"公司"）（股票简称：海南海药，股票 代码：000566）股票于 2025 年 11 月 14 日、11 月 17 日连续 2 个交易日收盘价 格涨幅偏离值累计达到 20%以上。根据深圳证券交易所（以下简称"深交所"） 的有关规定，属于股票交易异常波动情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司对有关事项进行了核查，并询问了公 司控股股东和实际控制人，现将相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、公司近期经营情况正常及内外部经营环境未发生重大变化。 5、股票异常波动期间，公司、控股股东、实际控制人未买卖公司股票。 三、不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任 ...

Market Overview - As of November 17, the Shanghai Composite Index closed at 3972.03 points, down 18.46 points, a decrease of 0.46% [1] - The Shenzhen Component Index closed at 13202.00 points, down 14.03 points, a decrease of 0.11% [1] - The ChiNext Index closed at 3105.20 points, down 6.30 points, a decrease of 0.20% [1] Stock Performance - A total of 85 A-shares had a turnover rate exceeding 20% on this day, with Northern Long Dragon achieving a turnover rate of over 50% [1] - The top stocks by turnover rate included: - Northern Long Dragon (301357) with a closing price of 175.77 CNY and a turnover rate of 55.11%, increasing by 19.57% [1] - Jianglong Shipbuilding (300589) with a closing price of 16.31 CNY and a turnover rate of 45.88%, increasing by 20.01% [1] - Sanmu Group (000632) with a closing price of 8.75 CNY and a turnover rate of 45.14%, increasing by 10.06% [1] - Fuxiang Pharmaceutical (300497) with a closing price of 21.15 CNY and a turnover rate of 42.80%, increasing by 12.14% [1] - Guqi Wool Material (001390) with a closing price of 27.52 CNY and a turnover rate of 42.58%, decreasing by 9.62% [1] Additional Notable Stocks - Other notable stocks with high turnover rates included: - Antai Group (600408) with a turnover rate of 41.06% and a price increase of 10.06% [1] - Qing Shui Yuan (300437) with a turnover rate of 40.77% and a price increase of 14.09% [1] - Kelong Co., Ltd. (300405) with a turnover rate of 40.63% and a price increase of 16.92% [1] - Zhongneng Electric (300062) with a turnover rate of 39.62% and a price decrease of 3.79% [1] - Danna Biotechnology (920009) with a turnover rate of 38.68% and a price increase of 1.28% [1]

Core Points - Hainan Haiyao announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory, has received approval from the National Medical Products Administration for the supplementary application of injectable Meropenem [2] - The approval confirms that the product has passed the consistency evaluation of quality and efficacy for generic drugs [2] Company Summary - Hainan Haiyao's subsidiary has successfully obtained a significant regulatory approval, which may enhance its product portfolio and market competitiveness [2] - The approval of injectable Meropenem indicates the company's commitment to maintaining high standards in drug quality and efficacy [2] Industry Summary - The approval reflects the ongoing efforts within the pharmaceutical industry to ensure that generic drugs meet stringent quality and efficacy standards [2] - This development may signal a positive trend for other companies in the industry seeking similar approvals for their products [2]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for the injectable drug Meropenem, which is used to treat various bacterial infections in adults and children [1] Group 1: Company Developments - Hainan Haiyao announced on November 14 that its wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the approval from the National Medical Products Administration for the supplemental application of injectable Meropenem [1] - The approval includes a notification for the drug's use in treating infections caused by single or multiple bacteria sensitive to Meropenem [1] Group 2: Product Information - Injectable Meropenem is indicated for the treatment of pneumonia (including hospital-acquired pneumonia), urinary tract infections, intra-abdominal infections, gynecological infections (such as endometritis and pelvic inflammatory disease), skin and soft tissue infections, meningitis, and sepsis [1]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new injectable antibiotic, Meropenem, which has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1: Company Developments - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has recently obtained the approval notice for the supplemental application of injectable Meropenem from the National Medical Products Administration [1] - The approved drug is indicated for infections caused by single or multiple bacteria sensitive to Meropenem in both adults and children [1]

证券代码：000566 证券简称：海南海药 公告编号：2025-069 海南海药股份有限公司关于子公司 注射用美罗培南通过仿制药质量和疗效一致性评价的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司近日获得国家药品监督管理局核准签发的化学药品注射用美罗培南的《药品 补充申请批准通知书》。现将相关情况公告如下： 一、药品基本情况 （一）药品名称：注射用美罗培南 二、 对公司的影响 1 剂型：注射剂 规格：0.25g、0.5g、1.0g 注册分类：化学药品 受理号：CYHB2550082、CYHB2550081、CYHB2550080 药品上市许可持有人：海口市制药厂有限公司 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。 （二）药品的其他相关情况 美罗培南为人工合成的广谱碳青霉烯类抗生素，通过抑制细菌细胞壁的合成 而产生抗菌作用，美罗培南容易穿透大多数革兰阳性和阴性细菌的细胞壁，而达 到其作用靶点青霉素结合蛋白（PBPs）。除金属β-内酰胺酶以外，其对大多数 β-内酰胺酶（包括由 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's injectable Meropenem, which is expected to enhance market competitiveness and positively impact the company's performance [1] Group 1: Regulatory Approval - The full-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the approval notice for the supplemental application of injectable Meropenem from the National Medical Products Administration [1] Group 2: Market Impact - The drug has passed the consistency evaluation, indicating that its quality and efficacy are equivalent to the original product, which will benefit the market competitiveness of the drug [1] - The approval is anticipated to have a positive effect on the company's performance [1]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for the injectable antibiotic Meropenem, which is a broad-spectrum carbapenem antibiotic effective against various bacterial infections [1] Group 1: Company Developments - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory, has obtained the approval from the National Medical Products Administration for the supplemental application of injectable Meropenem [1] - Meropenem is an artificially synthesized broad-spectrum carbapenem antibiotic that inhibits bacterial cell wall synthesis [1] Group 2: Product Characteristics - Meropenem is effective against most Gram-positive and Gram-negative bacteria by penetrating their cell walls to reach the target penicillin-binding proteins (PBPs) [1] - The antibiotic shows strong stability against most beta-lactamases, including those produced by both Gram-positive and Gram-negative bacteria [1] Group 3: Indications for Use - Injectable Meropenem is primarily indicated for infections in adults and children caused by single or multiple bacteria sensitive to Meropenem, including pneumonia, urinary tract infections, intra-abdominal infections, gynecological infections, skin and soft tissue infections, meningitis, and sepsis [1]